

# Karen Vanhoorelbeke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8276898/publications.pdf>

Version: 2024-02-01

97  
papers

3,945  
citations

147801

31  
h-index

128289

60  
g-index

98  
all docs

98  
docs citations

98  
times ranked

3785  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Autoantibody-Induced Pathology. <i>Frontiers in Immunology</i> , 2017, 8, 603.	4.8	377
2	ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. <i>Haematologica</i> , 2008, 93, 232-239.	3.5	250
3	Thrombotic thrombocytopenic purpura. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17020.	30.5	242
4	Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure*. <i>Critical Care Medicine</i> , 2007, 35, 2375-2382.	0.9	167
5	Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. <i>Haematologica</i> , 2020, 105, 498-507.	3.5	154
6	ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. <i>Blood</i> , 2016, 127, 2337-2345.	1.4	138
7	ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. <i>British Journal of Haematology</i> , 2007, 138, 534-540.	2.5	135
8	Allosteric activation of ADAMTS13 by von Willebrand factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18584-18589.	7.1	123
9	Conformational activation of ADAMTS13. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18578-18583.	7.1	111
10	Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio Tj ETQq0 0 0 rgBT /Overlock 10	1.4	104
11	Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. <i>Blood</i> , 2018, 132, 2143-2153.	1.4	102
12	Adhesion of Staphylococcus aureus to the vessel wall under flow is mediated by von Willebrand factor-binding protein. <i>Blood</i> , 2014, 124, 1669-1676.	1.4	96
13	Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. <i>Blood</i> , 2017, 130, 466-471.	1.4	92
14	ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 955-962.	3.8	86
15	Multi-step binding of ADAMTS-13 to von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 2088-2095.	3.8	79
16	An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 378-388.	3.8	72
17	Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy. <i>Circulation</i> , 2014, 129, 1320-1331.	1.6	69
18	Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. <i>Blood</i> , 2015, 126, 1715-1722.	1.4	65

#	ARTICLE	IF	CITATIONS
19	Restoration of Plasma von Willebrand Factor Deficiency Is Sufficient to Correct Thrombus Formation After Gene Therapy for Severe von Willebrand Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1621-1626.	2.4	64
20	Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2336-2342.	2.4	64
21	Binding of von Willebrand Factor to Collagen and Glycoprotein Ibf $\pm$ , But Not to Glycoprotein IIb/IIIa, Contributes to Ischemic Stroke in Miceâ€”Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1949-1951.	2.4	63
22	Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTSâ€“13. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2063-2075.	3.8	58
23	Crystal structure and substrate-induced activation of ADAMTS13. <i>Nature Communications</i> , 2019, 10, 3781.	12.8	56
24	N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. <i>Blood</i> , 2017, 129, 1030-1038.	1.4	53
25	Animal models for thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2-10.	3.8	52
26	First report of a de novo iTTP episode associated with an mRNAâ€“based antiâ€“COVIDâ€“19 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2014-2018.	3.8	52
27	Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice. <i>Stroke</i> , 2016, 47, 2419-2422.	2.0	48
28	Local Elongation of Endothelial Cell-anchored von Willebrand Factor Strings Precedes ADAMTS13 Protein-mediated Proteolysis. <i>Journal of Biological Chemistry</i> , 2011, 286, 36361-36367.	3.4	46
29	Inhibition of von Willebrand factorâ€“platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. <i>Blood</i> , 2012, 120, 3611-3614.	1.4	40
30	ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshawâ€“Schulman Syndrome. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1902-1917.	3.4	40
31	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. <i>Blood</i> , 2020, 136, 353-361.	1.4	35
32	Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVIDâ€“19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2193-2198.	3.8	33
33	Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. <i>Haematologica</i> , 2018, 103, 1099-1109.	3.5	31
34	Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function. <i>Blood Advances</i> , 2020, 4, 1072-1080.	5.2	28
35	The role of platelet and endothelial GARP in thrombosis and hemostasis. <i>PLoS ONE</i> , 2017, 12, e0173329.	2.5	27
36	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1729-1742.	3.4	24

#	ARTICLE	IF	CITATIONS
37	Crystal structure of ADAMTS13 CUB domains reveals their role in global latency. <i>Science Advances</i> , 2021, 7, .	10.3	24
38	Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are functionally active in an ex vivo flow model of thrombosis. <i>Blood</i> , 2009, 114, 5044-5051.	1.4	23
39	ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura – current perspectives and new treatment strategies. <i>Expert Review of Hematology</i> , 2016, 9, 209-221.	2.2	23
40	Exploring the –minimal– structure of a functional ADAMTS13 by mutagenesis and small-angle X-ray scattering. <i>Blood</i> , 2019, 133, 1909-1918.	1.4	23
41	Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation. <i>Blood</i> , 2019, 133, 1899-1908.	1.4	23
42	Expanding a Portfolio of (FO-) SPR Surface Chemistries with the Co(III)-NTA Oriented Immobilization of His <sub>6</sub> -Tagged Bioreceptors for Applications in Complex Matrices. <i>ACS Sensors</i> , 2020, 5, 960-969.	7.8	23
43	Super-resolution mapping of glutamate receptors in <i>C. elegans</i> by confocal correlated PALM. <i>Scientific Reports</i> , 2015, 5, 13532.	3.3	21
44	Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 836-844.	2.4	19
45	Co(III)-NTA Mediated Antigen Immobilization on a Fiber Optic-SPR Biosensor for Detection of Autoantibodies in Autoimmune Diseases: Application in Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>Analytical Chemistry</i> , 2020, 92, 13880-13887.	6.5	19
46	The novel ADAMTS13 –p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 283-292.	3.8	17
47	Understanding therapeutic targets in thrombotic thrombocytopenic purpura. <i>Intensive Care Medicine</i> , 2017, 43, 1398-1400.	8.2	17
48	Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ. <i>Haematologica</i> , 2018, 103, 1083-1092.	3.5	17
49	ADAMTS13 in Health and Disease. <i>Acta Haematologica</i> , 2009, 121, 183-185.	1.4	16
50	Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura. <i>Thrombosis and Haemostasis</i> , 2018, 118, 028-041.	3.4	16
51	Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura. <i>Haematologica</i> , 2020, 105, 2619-2630.	3.5	16
52	Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 478-488.	3.8	16
53	Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura. <i>Blood Advances</i> , 2021, 5, 3427-3435.	5.2	16
54	Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis. <i>Blood</i> , 2022, 139, 597-607.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 009-017.	2.7	15
56	Tuning the Surface Interactions between Single Cells and an OST-E+ Microwell Array for Enhanced Single Cell Manipulation. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 2316-2326.	8.0	15
57	Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2432-2442.	3.8	14
58	Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis. <i>Blood Advances</i> , 2021, 5, 3478-3491.	5.2	14
59	Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura. <i>PLoS ONE</i> , 2016, 11, e0160388.	2.5	14
60	ADAMTS13 glycans and conformation-dependent activity. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1155-1166.	3.8	13
61	Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1397-1408.	3.4	13
62	Deletion of platelet CLEC-2 decreases GPIIb-mediated integrin $\alpha$ IIb $\beta$ 3 activation and decreases thrombosis in TTP. <i>Blood</i> , 2022, , .	1.4	13
63	Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 985-990.	3.8	12
64	Evaluation of Immuno-Rolling Circle Amplification for Multiplex Detection and Profiling of Antigen-Specific Antibody Isotypes. <i>Analytical Chemistry</i> , 2021, 93, 6169-6177.	6.5	12
65	<sc>TTP</sc>: From empiricism for an enigmatic disease to targeted molecular therapies. <i>British Journal of Haematology</i> , 2022, 197, 156-170.	2.5	12
66	Thrombus formation during ECMO: Insights from a detailed histological analysis of thrombus composition. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2058-2069.	3.8	12
67	Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of Pregnancy-Onset Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>TH Open</i> , 2018, 02, e8-e15.	1.4	11
68	N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP. <i>Blood</i> , 2021, 137, 2694-2698.	1.4	11
69	Gold nanoparticle enhanced multiplexed biosensing on a fiber optic surface plasmon resonance probe. <i>Biosensors and Bioelectronics</i> , 2021, 192, 113549.	10.1	11
70	Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management. <i>Current Opinion in Hematology</i> , 2020, 27, 320-326.	2.5	10
71	Miniaturized single-cell technologies for monoclonal antibody discovery. <i>Lab on A Chip</i> , 2021, 21, 3627-3654.	6.0	10
72	Structure-Based Cyclic Glycoprotein I $\beta$ -Derived Peptides Interfering with von Willebrand Factor-Binding, Affecting Platelet Aggregation under Shear. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2046.	4.1	10

#	ARTICLE	IF	CITATIONS
73	In vivo von Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS-13. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2506-2508.	3.8	9
74	Improved molecular platform for the gene therapy of rare diseases by liver protein secretion. <i>European Journal of Medical Genetics</i> , 2018, 61, 723-728.	1.3	9
75	Generation and validation of small ADAMTS13 fragments for epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 918-930.	2.3	9
76	Deletion of GARP on mouse regulatory T cells is not sufficient to inhibit the growth of transplanted tumors. <i>Cellular Immunology</i> , 2018, 332, 129-133.	3.0	8
77	von Willebrand factor in experimental malaria-associated acute respiratory distress syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1372-1383.	3.8	8
78	Determination of anti-ADAMTS-13 autoantibody titers in ELISA: Influence of ADAMTS-13 presentation and autoantibody detection. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2248-2255.	3.8	7
79	Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 762-766.	2.3	6
80	Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency. <i>Thrombosis and Haemostasis</i> , 2021, 121, 182-191.	3.4	6
81	Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP. <i>Blood Advances</i> , 2021, 5, 4480-4484.	5.2	6
82	Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. <i>Haematologica</i> , 2019, 104, 1268-1276.	3.5	5
83	ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology. <i>Haematologica</i> , 2023, 108, 638-644.	3.5	5
84	von Willebrand factor deficiency does not influence angiotensin II-induced abdominal aortic aneurysm formation in mice. <i>Scientific Reports</i> , 2018, 8, 16645.	3.3	4
85	Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13. <i>European Journal of Haematology</i> , 2018, 101, 191-199.	2.2	4
86	Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura. <i>HemaSphere</i> , 2020, 4, e462.	2.7	4
87	Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101132.	3.4	4
88	von Willebrand factor increases in experimental cerebral malaria but is not essential for late-stage pathogenesis in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2377-2390.	3.8	2
89	Single Particle Tracking of ADAMTS13 (A Disintegrin and Metalloprotease with Thrombospondin Type-1) Tj ETQq1 1 0.784314 rgBT /Ove 2014, 289, 8903-8915.	3.4	1
90	Response to Letter Regarding Article, "Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy". <i>Circulation</i> , 2015, 131, e19-20.	1.6	1

#	ARTICLE	IF	CITATIONS
91	PROFILE: Early-Stage Researchers Advancing Insights in TTP Through a Unique PhD Track. HemaSphere, 2018, 2, e22.	2.7	1
92	Acquired von Willebrand syndrome in patients on long-term left ventricular assist device support: Results of a Belgian center. Thrombosis Research, 2019, 184, 77-80.	1.7	1
93	Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation. Haematologica, 2019, 104, e277-e280.	3.5	1
94	Update - PROFILE: Early-Stage Researchers Advancing Insights on TTP through a Unique PhD Track. HemaSphere, 2019, 3, e281.	2.7	1
95	Artificial MiRNA Knockdown of Platelet Glycoprotein Ib: A Tool for Platelet Gene Silencing. PLoS ONE, 2015, 10, e0132899.	2.5	0
96	P5119 Differences in VWF activity in von willebrand disease type 2A patients versus LVAD patients with the acquired von willebrand syndrome. European Heart Journal, 2018, 39, .	2.2	0
97	Improvement of recombinant ADAMTS13 production through a more optimal signal peptide or an N-terminal fusion protein. Journal of Thrombosis and Haemostasis, 0, , .	3.8	0